Xbrane Biopharma (Q3 update): Headwinds have continued - Redeye

Redeye provides an update on Xbrane following the Lucamzi CRL and its Q3 report. The outlook for Xbrane’s ranibizumab biosimilar has become increasingly challenging, reflected in the sharp decline in the company’s valuation. As market confidence in Ximluci has waned, Xdivane is emerging as an increasingly important component of the investment case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1132701/xbrane-biopharma-q3-update-continuing-headwinds?utm_source=finwire&utm_medium=RSS